Please update your Flash Player to view content.

Upcoming Events:

There are no upcoming events.

Bio Pro Classes:

 
Wednesday, 16 Apr 2014
Category: Bio Pro Classes

 
Wednesday, 16 Apr 2014
Category: Bio Pro Classes

 
Thursday, 17 Apr 2014 - Friday, 18 Apr 2014
Category: Bio Pro Classes

 
Tuesday, 22 Apr 2014
Category: Bio Pro Classes

 
Tuesday, 22 Apr 2014
Category: Bio Pro Classes

 
Thursday, 24 Apr 2014 - Friday, 25 Apr 2014
Category: Bio Pro Classes

 
Thursday, 08 May 2014
Category: Bio Pro Classes

 
Friday, 16 May 2014
Category: Bio Pro Classes

 
Thursday, 22 May 2014
Category: Bio Pro Classes

 
Thursday, 05 Jun 2014 - Friday, 06 Jun 2014
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

Registration now open!

BioForum: ISPE and Oregon Bio at Genentech

Genentech exteriorThe Oregon Bioscience Association has teamed up with the Pacific North West Chapter of the International Society for Pharmaceutical Engineers (ISPE) and Genentech to bring you this exciting event - a first of its kind.  Join us to tour the Hillsboro Technical Operations (HTO) facility and learn about the latest innovations in aseptic processing, automated inspection, packaging and serialization, and more.  There will be ample opportunity for networking and learning more about the Oregon Bioscience Association and ISPE.ISPE 2010 PacificNW Chtr cropped

When: Thursday May 8, 2014, 6-9 p.m.
Where: Genentech Hillsboro, 4625 NW Brookwood Parkway, Hillsboro OR 97124
Admission: $45 Members, $70 Non-members, $15 Students

  • Attendees must present a government issued photo ID upon arrival at the event. 
    Entry will not be allowed without a valid ID.
  • Parking is available in paved lots in front of Genentech;
    additional parking is available in the gravel lot off of Evergreen Parkway. 
  • Registration will close on May 5th.  Space is limited, so register today.

Agenda:
6:00 – 6:30: Networking and registration
6:30 – 7:30: Formal presentations
7:30 – 9:00: Open house/window tour and networking

Sponsorship opportunities available!
Please contact Julie Black at
This email address is being protected from spambots. You need JavaScript enabled to view it. for more information 

Register Now button 

 

 

 

 Thanks to our sponsors:

Gold Level:  

      
 

 
 genentech125x150
Silver Level:
CAI Logo

News Flash

  • DesignMedix awarded $3 million to develop low-cost, safe malaria drug

    Portland, Oregon, April 15, 2014 — DesignMedix, Inc., a biotech startup with ties to Portland State University, received a grant for almost $3 million from the National Institutes of Health to continue development and manufacture of a new anti-malarial drug.

    “Each year, over 600,000 children under the age of five die of malaria,” said Dr. Sandra Shotwell, president and COO of DesignMedix. “Our new drug will provide another weapon to target this deadly disease, which kills more young children than any other.”

    The drug in development is as a low cost cure for drug-resistant malaria that is as safe as chloroquine, a frontline drug that used for many years until rendered ineffective by drug resistance. Malaria drug resistance — widespread in Africa and Asia — is created by a mutation that causes rapid transport of the drug out of the malaria cells, rendering the drug ineffective. The DesignMedix technology approach creates a new drug that inhibits the transport and overcomes the drug resistance.

    DesignMedix will share the three-year grant with the chemistry lab of PSU professor David Peyton, who invented the technology and co-founded the company. Three patents have been issued relating to the drug molecules, and DesignMedix has exclusive rights to develop the technology.

    “I am very pleased that NIH has continued to support this work in such a significant way,” said Peyton, who has been working on malaria for more than 15 years.

    Several malaria drugs currently are available from large multinational and Indian drug manufacturers. Most current therapies show drug resistance, and some cost up to tenfold more than the cost projected for DesignMedix’s drug. This drug has high potential to be a good partner drug for existing or pipeline malaria drugs to both overcome drug resistance, and reduce cost. DesignMedix has partnered with Oregon Consultants Inc. (OCI) of Eugene, Oregon to produce material for preclinical and clinical studies.

     About DesignMedix Inc.

    DesignMedix, Inc was founded in 2008 to develop drugs to overcome drug resistance. The company’s initial focus is on oral drugs to treat malaria, which kills over 600,000 people per year and affects up to 500 million people. The company has developed a series of novel, safe and effective drugs that have the potential for low-cost production. For more information please visit http://www.designmedix.com

    The Advanced Technology Phase II award from the National Institutes and Allergy and Infectious Disease (NIAID) is part of the Small Business Technology Transfer Program of the NIH. Research reported in this release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under Award Number R41AI094959. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Bioscience News

  • Leveraging Small Business to Bring Life-Saving Innovations to the Market. A key part of the National Institutes of Health (NIH) and the National Science Foundation (NSF)’s mission is the translation of basic discoveries into innovative technologies that improve human health, and the NIH and NSF Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) programs strive to do just that. NIH is the premier biomedical research funding organization in the world, and has a 2014 SBIR/STTR Read More >

  • In a recent article, published by Globalpost, John Otis writes on how the small town of Jacobina, Brazil used agricultural biotechnology to help control the occurrence of Dengue Fever. By releasing swarms of mosquitoes engineered to wipe out their own species, Jacobina farmers will be better able to carry out their daily duties with a reduced risk of acquiring the disease.  “We need to provide alternatives because the system we have now in Brazil doesn’t Read More >

  • The BIO International Convention is all about raising your profile, making connections, and moving your business forward. One of the more creative and fun ways for companies to accomplish these goals is the annual Buzz of BIO contest. This is an online voting contest for the industry to cast their pick for this year’s most creative biotech company. Prizes This year, there are two categories: Pipelines of Promise, and Technologies of Tomorrow. One company from each of Read More >

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2012. All Rights Reserved.